Similarly, ABL1, part of the BCR-ABL target of imatinib, an early immunotherapy, had the top impact score in both datasets with chronic myeloid leukemia. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.